


Supplementary Figure S4



Supplementary Figure S4. MET inhibitor improved the efficacy of immunotherapy in tumor with MET amplification/overexpression in vitro

A, The expression of PD-L1 in Lewis cells from the MET OE and MET control cells after anti-PD1 treatment.

B, H1993 cells were first treated with or without MET inhibitor tivantinib (TTB) (50 nM) for 48 hours followed by treated with or without anti-PD-1 antibody (PD-1 Ab; 10 μ g/mL) and co-cultured with activated PBMCs for 7 days. (Unpaired, two-tailed Student's t-tests; * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$).

C, Tumor cells from a patient with MET amplification were first treated with or without MET inhibitor tivantinib (TTB) (50 nM) for 48 hours followed by treating with or without anti-PD-1 antibody (PD-1 Ab; 10 μ g/mL) and co-cultured with activated autogenous PBMCs with or without STING knocked down for 7 days. (Unpaired, two-tailed Student's t-tests; * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$).